pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·8h ago·1 min read
save

‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loom

Nov 20, 2026·read at Fierce Biotech ↗

As the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 11h agoBausch + Lomb and Celldex rocked by respective phase 2 flopsFierce Biotech
  • 22h agoAnthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’Fierce Biotech
  • 22h agoChutes & Ladders—Teva loses R&D head as innovation pivot advancesFierce Biotech
  • 1d agoVaccine biotech Evaxion halts infectious disease, autoimmune work to focus on oncologyFierce Biotech
  • 1d agonChroma halves headcount, calls time on trial of potential HBV ‘cure’Fierce Biotech